Alopecia Areata (AA) is a chronic autoimmune disorder causing non-scarring hair loss. Conventional AA treatments show limited efficacy, highlighting the need for more effective therapeutic options. Ritlecitinib, an oral JAK3/TEC family kinase inhibitor, demonstrated efficacy and safety in patients aged ≥12 years, with data available up to 48 weeks. However, real-life investigation into its effectiveness and safety are limited. This study sought to address this knowledge gap by investigating treatment outcomes among AA patients undergoing ritlecitinib in a real-life setting. For this purpose, we performed a retrospective chart review across 3 Italian tertiary referral centers. Compared to the ALLEGRO trial, a higher rate of SALT20 responses has been observed.
Valtellini, L., Avallone, G., Murgia, G., Perego, G., Giunipero Di Corteranzo, I., Vignoli, C.A., et al. (2025). Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 50(11), 2297-2300 [10.1093/ced/llaf312].
Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
Gallo G.;Ferrucci S. M.
2025
Abstract
Alopecia Areata (AA) is a chronic autoimmune disorder causing non-scarring hair loss. Conventional AA treatments show limited efficacy, highlighting the need for more effective therapeutic options. Ritlecitinib, an oral JAK3/TEC family kinase inhibitor, demonstrated efficacy and safety in patients aged ≥12 years, with data available up to 48 weeks. However, real-life investigation into its effectiveness and safety are limited. This study sought to address this knowledge gap by investigating treatment outcomes among AA patients undergoing ritlecitinib in a real-life setting. For this purpose, we performed a retrospective chart review across 3 Italian tertiary referral centers. Compared to the ALLEGRO trial, a higher rate of SALT20 responses has been observed.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
